Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 6Phase 3 2Phase 1/2 1

Status

Completed 3Active not recruiting 2Terminated 1

Sponsor Class

OTHER 4NIH 1INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6

Conditions

Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Myelodysplastic Syndromes 19Lymphoma, Non-Hodgkin 17Leukemia, Lymphocytic, Chronic, B-Cell 15Hodgkin Disease 15Graft vs Host Disease 13Lymphoma, Mantle-Cell 12Leukemia 12Multiple Myeloma 11Lymphoma, Large B-Cell, Diffuse 11Sarcoma 10Lymphoma 10Lymphoma, Follicular 9Lymphoma, B-Cell, Marginal Zone 9Burkitt Lymphoma 9Myeloproliferative Disorders 8Waldenstrom Macroglobulinemia 7Tuberous Sclerosis 7Neoplasms 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Hematologic Neoplasms 7Congenital Abnormalities 7Primary Myelofibrosis 6Lymphoma, Large-Cell, Immunoblastic 6Leukemia, Myelomonocytic, Chronic 6Leukemia, Myeloid, Chronic-Phase 6Leukemia, Myeloid, Accelerated Phase 6Breast Neoplasms 6Osteosarcoma 5

Interventions

Trastuzumab 303Paclitaxel 256Cyclophosphamide 251Docetaxel 238Capecitabine 175Letrozole 163Carboplatin 163Doxorubicin 145Fulvestrant 144Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 88Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 44Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × Sirolimus × Clear all
NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

University of Miami

Phase 2 Active not recruiting
24 enrolled
Breast

Breast Neoplasms

NCT06957379 2025-05-04

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Active not recruiting
78 enrolled
Breast

Breast Neoplasms

NCT02642094 2023-12-05

Aging Mammary Stem Cells and Breast Cancer Prevention

The University of Texas Health Science Center at San Antonio

Phase 2 Terminated
58 enrolled 11 charts
Breast

Breast Neoplasms

NCT00376688 2020-02-24

Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
31 enrolled 5 charts
Breast

Breast Neoplasms

NCT01797120 2018-05-30

PrE0102

PrECOG, LLC.

Phase 2 Completed
131 enrolled 12 charts
Breast

Breast Neoplasms

NCT00411788 2016-09-21

A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer

Yale University

Phase 2 Completed
11 enrolled 8 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡